Home Report Catalogue APAC RNA Interference Therapeutics Market Analysis
Pharmaceuticals APAC

APAC RNA Interference Therapeutics Market Analysis, 2024–2034

APAC RNA Interference Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $993.8 Mn Estimated value
Estimate 2025 $1.21 Bn 20.9% of the global market
Projected 2034 $6.85 Bn 468.5% Adds $5.65 Bn over 9 forecast years
CAGR 2025–2034 21.3% Faster than 87% of 180 Pharmaceuticals markets here
Key players 5
  • APAC is 20.93% of the global market.
  • Among regions, the largest is North America at $3.15 Bn.
  • Fastest growing: Africa at 21.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$5.65 Bn total, 2026–2034

Year-by-year market size, 2024–2034
RNA Interference Therapeutics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $993.8 Mn — —
2025 (base) $1.21 Bn +$211.7 Mn —
2026 (forecast) $1.46 Bn +$256.8 Mn +21.3%
2027 (forecast) $1.77 Bn +$311.5 Mn +47.1%
2028 (forecast) $2.15 Bn +$377.8 Mn +78.5%
2029 (forecast) $2.61 Bn +$458.3 Mn +116.5%
2030 (forecast) $3.17 Bn +$555.9 Mn +162.6%
2031 (forecast) $3.84 Bn +$674.3 Mn +218.5%
2032 (forecast) $4.66 Bn +$817.9 Mn +286.4%
2033 (forecast) $5.65 Bn +$992.1 Mn +368.7%
2034 (forecast) $6.85 Bn +$1.20 Bn +468.5%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $5.76 Bn
  2. North America $3.15 Bn
  3. US $2.04 Bn
  4. APAC (this report) $1.21 Bn
  5. Europe $916.4 Mn
  6. China $461.5 Mn
  7. Canada $445.4 Mn
  8. Japan $320.4 Mn
  9. Latin America $250.8 Mn
  10. Middle East $234.1 Mn
  11. Germany $212.2 Mn
  12. UK $151.5 Mn
  13. France $149.6 Mn
  14. Brazil $153.7 Mn
  15. Italy $135.7 Mn
  16. Ecuador $123.5 Mn
  17. Saudi Arabia $112.4 Mn
  18. Spain $105.4 Mn
  19. India $110.4 Mn
  20. Africa $86.1 Mn
  21. Mexico $74.7 Mn
  22. Australia $63.3 Mn
  23. Russia $59.8 Mn
  24. New Zealand $59.8 Mn
  25. South Africa $37.5 Mn
  26. UAE $25.3 Mn
  27. Egypt $16.0 Mn
  28. Philippines $14.3 Mn
  29. Malaysia $10.5 Mn
  30. Hong Kong $9.0 Mn
  31. Singapore $8.0 Mn
  32. Thailand $6.5 Mn
  33. Kenya $4.4 Mn

The APAC RNA Interference Therapeutics Market Analysis Executive Summary

RNA interference therapeutics use small RNA molecules to switch off disease-causing genes, used in rare, heart and liver diseases.

Key segments of the RNA Interference Therapeutics market include molecule (siRNA, Antisense Oligonucleotides and microRNA) and indication (Rare Genetic Diseases, Cardiovascular and Liver Diseases).

APAC RNA Interference Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the RNA Interference Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the RNA Interference Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for RNA Interference Therapeutics Market in APAC

The RNA Interference Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for RNA Interference Therapeutics Market in APAC

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RNA Interference Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about RNA Interference Therapeutics in APAC? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in APAC

See all
Same topic, other categories

Related on biologics and biosimilars and genomics

See the topic